Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Summit Therapeutics plc : Director/PDMR Shareholding


Posted on: 23 Apr 18

Summit Therapeutics plc
('Summit' or the 'Company')
                                                                                                 
Exercise of Share Options

Oxford, UK, and Cambridge, MA, US, 23 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces the exercise by the following Non-Executive Directors of share options over the Company's ordinary shares of one penny nominal value granted under the Company's 2005 share option scheme. None of the new ordinary shares were sold by the Non-Executive Directors. The exercise of the options is in line with the stated intention of the Non-Executive Directors to advance the Company's objective of meeting best UK corporate governance practice that favours non-performance remuneration, such as restricted stock units.

    Number of Exercised Options Number of Outstanding Options held New Total Shareholding % of Issued Share Capital
Barry Price Non-Executive Director 31,481 Nil 107,211 0.13%
Stephen Davies Non-Executive Director 17,500 Nil 602,481 0.74%

The admission of these new ordinary shares to trading on AIM is covered by the Company's existing block listing application. Following the exercise of these share options, the total number of options capable of vesting under the Company's 2005 and 2016 share option schemes is now 10,009,284.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit    
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)   +1 617 225 4455
     
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson    

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Barry Price
2 Reason for the notification
a) Position / status Non-Executive Director
b) Initial notification / Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Summit Therapeutics plc
b) LEI 213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1 penny each
  
Identification code GB00BN40HZ01
b) Nature of the transactions Exercise and hold of share options
c) Price(s) and volume(s)   Price(s) Volume(s)  
65 pence (exercise price)
126 pence (exercise price)
13,981
17,500
 
d) Aggregated information  
- Aggregated volume 31,481 ordinary shares
- Price £31,137.65 (being an average subscription price of 98.9 pence per share)
e) Date of the transaction 23 April 2018
f) Place of the transaction Outside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Professor Stephen Davies
2 Reason for the notification
a) Position / status Non-Executive Director
b) Initial notification / Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Summit Therapeutics plc
b) LEI 213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1 penny each
  
Identification code GB00BN40HZ01
b) Nature of the transactions Exercise and hold of share options
c) Price(s) and volume(s)   Price(s) Volume(s)  
126 pence (exercise price) 17,500
 
d) Aggregated information  
- Aggregated volume N/A
- Price  
e) Date of the transaction 23 April 2018
f) Place of the transaction Outside a trading venue

-END-

GlobeNewswire
globenewswire.com

Last updated on: 24/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.